Message

From: psmatthancock [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=8DDDC7F87798480280E3A7AA57CB8D62-PSMATTHANCO]
Sent: 17/03/2020 22:30:28
To: Sharon Peacock [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b25d70f692447469261ae948c92dcd3-Sharon Peac]; MEDICALDIRECTOR2, England (NHS ENGLAND & NHS IMPROVEMENT - X24) [england.medicaldirector2@nhs.net]; Oldfield, Steve [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e53f3b0e01c74d5ba7c94c7cd14c524b-SOldfield]; Hadley Beeman [hadley.beeman@nhsx.nhs.uk]; Name Redacted /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9ec3823a6ea9440b9e044d6a88d08ca9 Name Redacted PsBethell [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6f0a1735f9834b5ca9c02d2016d42e9f-PsBethell]; June Raine [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d4ac687ee354c9cac76d09f23ee6ade-June Raine]; Whitty, Chris [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0b3ee62e0ca04e978730b14f9b416a1e-Whitty, Chr]; NR [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d21258c9254e4e32942f15c21ee78f6 NR]; Government Chief Scientific Adviser (GO-Science) [GCSA I&S ; Duncan Selbie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=402d500ef6d3426b81ab39cfd0f5bcf5-Duncan Selb] Name Redacted Name Redacted @phe.gov.uk]; William Warr [WWarr@no10.gov.uk]; Name Redacted @no10.gov.uk]; Imran Shafi [IShafi@no10.gov.uk]; Simon Eccles [simon.eccles@nhsx.nhs.uk]; Fowler, Aidan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b1153bf5f6d34a1dab23cf34073eaa9e-AFowler5]
CC: Permanent Secretary [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c95fac41d7c24f8ba5faa2072856bcdf-Permanent S]; PsBethell [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6f0a1735f9834b5ca9c02d2016d42e9f-PsBethell]; Name Redacted Name Redacted @nhsx.nhs.uk]; Name Redacted [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d93ca8c4416b4aa2ac18528d0ee80c18 NR ; Senior Copylist [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=45360eff9fa2467d8fead1fe51e67238-NEWSeniorCo]
Subject: Brief readout from no10 mass testing roundtable

All,

In the interests of time I'm only to send round the four key actions from the mass testing roundtable in no10 this evening. Please do shout if you think I've misrepresented any of the points, and note that for now I haven't shared this with industry.

1. NR and team are looking at the best kitemarked products on the market for testing those who have had the condition and will have a list tomorrow of those appropriate. She will then work with **Steve Oldfield** to purchase. The first call is for key workers in the NHS to have access to the testing to help people return to work. NR and **Steve Powis** to work out a plan for this.
2. **Jeremy Farrar** to lead on the research point, looking at a serology based survey across the population, with input from NR as necessary.
3. **Hadley** to talk to NR and NR about mass serology testing through at home kits, ensuring that it links back into the NHS through the work NHSX is leading on.
4. **Lord Bethell, Jeremy Farrar** and NR to come up with a plan for the fastest way to scale up antigen testing (the "do you have it now" test) using entirely non NHS/PHE facilities, starting with Thermofisher possible capacity.

Other key points
i. NR is leading on the work around 'do you have it now' testing.

ii. NR has said the MHRA will publish performance specs to allow companies to get involved as fast as possible.
iii. CMO has said it's important for the most accurate tests (as it will take time to develop accuracy) to be used on NHS staff and those who are vulnerable.
iv. Companies had concerns about shortages of products for the process e.g. swabs and reagents.
v. NR to look at how swabs are being used across the system
vi. Name Redacted said Universities can explore how their capacity can be used.

Many thanks
Kitty

Department of Health & Social Care

Kitty Hilton

Private Secretary to Secretary of State for Health and Social Care
9th Floor, 39 Victoria Street, SW1H 0EU
E: katya.hilton@dhsc.gov.uk T: Irrelevant & Sensitive

DHSC recipients please note: this email will not be saved by Private Office. If you need it for audit purposes, please keep a copy for your records.